CZ422598A3 - Protein ihnibující p27, DNA kódující takový protein a jejich použití k průkazu RNA, pro hledání inhibitorů a ke stimulaci buněčné proliferace - Google Patents

Protein ihnibující p27, DNA kódující takový protein a jejich použití k průkazu RNA, pro hledání inhibitorů a ke stimulaci buněčné proliferace Download PDF

Info

Publication number
CZ422598A3
CZ422598A3 CZ984225A CZ422598A CZ422598A3 CZ 422598 A3 CZ422598 A3 CZ 422598A3 CZ 984225 A CZ984225 A CZ 984225A CZ 422598 A CZ422598 A CZ 422598A CZ 422598 A3 CZ422598 A3 CZ 422598A3
Authority
CZ
Czechia
Prior art keywords
protein
ser
thr
sequence
asp
Prior art date
Application number
CZ984225A
Other languages
Czech (cs)
English (en)
Inventor
Martin Prof. Dr. Eilers
Andrea Buergin
Hans-Harald Prof. Dr. Sedlacek
Original Assignee
Hoechst Marion Roussel Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Deutschland Gmbh filed Critical Hoechst Marion Roussel Deutschland Gmbh
Publication of CZ422598A3 publication Critical patent/CZ422598A3/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
CZ984225A 1997-12-20 1998-12-18 Protein ihnibující p27, DNA kódující takový protein a jejich použití k průkazu RNA, pro hledání inhibitorů a ke stimulaci buněčné proliferace CZ422598A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19756975A DE19756975A1 (de) 1997-12-20 1997-12-20 Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie einer Erkrankung

Publications (1)

Publication Number Publication Date
CZ422598A3 true CZ422598A3 (cs) 1999-07-14

Family

ID=7852804

Family Applications (2)

Application Number Title Priority Date Filing Date
CZ984223A CZ422398A3 (cs) 1997-12-20 1998-12-18 Konstrukty nukleové kyseliny, jejichž aktivita je ovlivněna inhibitory kináz závislých na cyklinu, způsob přípravy takových konstruktů a jejich použití pro přípravu léčiva
CZ984225A CZ422598A3 (cs) 1997-12-20 1998-12-18 Protein ihnibující p27, DNA kódující takový protein a jejich použití k průkazu RNA, pro hledání inhibitorů a ke stimulaci buněčné proliferace

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CZ984223A CZ422398A3 (cs) 1997-12-20 1998-12-18 Konstrukty nukleové kyseliny, jejichž aktivita je ovlivněna inhibitory kináz závislých na cyklinu, způsob přípravy takových konstruktů a jejich použití pro přípravu léčiva

Country Status (15)

Country Link
US (1) US6265562B1 (hu)
EP (2) EP0926237A3 (hu)
JP (2) JPH11313686A (hu)
KR (2) KR19990063285A (hu)
CN (2) CN1225367A (hu)
AR (2) AR017887A1 (hu)
AU (2) AU747246B2 (hu)
BR (2) BR9805152A (hu)
CA (2) CA2255141A1 (hu)
CZ (2) CZ422398A3 (hu)
DE (1) DE19756975A1 (hu)
HU (1) HUP9802961A3 (hu)
ID (2) ID21582A (hu)
PL (2) PL330451A1 (hu)
TR (2) TR199802649A2 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19751587A1 (de) 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme
GB9727512D0 (en) * 1997-12-31 1998-02-25 Adprotech Plc Fuzzy genes and their application in molecular adjuvants
DE19831420A1 (de) * 1998-07-14 2000-01-20 Hoechst Marion Roussel De Gmbh Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
GB0025229D0 (en) * 2000-10-14 2000-11-29 Adprotech Ltd Veterinary immunisation vectors
US20030113784A1 (en) * 2001-11-29 2003-06-19 Jaime Flores-Riveros Regulated expression of recombinant DNA
EP2386564B1 (en) * 2005-10-01 2014-07-16 Charles Stout Regulatable fusion promoters
JP2010525812A (ja) 2007-05-02 2010-07-29 メリアル リミテッド 発現及び安定性が改善されたdnaプラスミド
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
AU2018205629A1 (en) * 2017-01-03 2019-07-11 Bioatla Llc Protein therapeutics for treatment of senescent cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
DE19524720A1 (de) 1995-07-12 1997-01-16 Hoechst Ag Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3"
DE19605274A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
DE19751587A1 (de) * 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme

Also Published As

Publication number Publication date
HU9802961D0 (en) 1999-02-01
CN1227871A (zh) 1999-09-08
US6265562B1 (en) 2001-07-24
JPH11313686A (ja) 1999-11-16
AU758030B2 (en) 2003-03-13
BR9805151A (pt) 2000-03-21
TR199802649A3 (tr) 1999-07-21
CA2255141A1 (en) 1999-06-20
EP0926237A3 (de) 2000-01-05
TR199802648A3 (tr) 1999-07-21
AU9720498A (en) 1999-07-08
AR017887A1 (es) 2001-10-24
EP0926236A1 (de) 1999-06-30
DE19756975A1 (de) 1999-06-24
AU747246B2 (en) 2002-05-09
BR9805152A (pt) 2000-03-21
KR19990063285A (ko) 1999-07-26
ID21582A (id) 1999-06-24
ID21534A (id) 1999-06-24
JPH11308997A (ja) 1999-11-09
HUP9802961A3 (en) 2000-04-28
CN1225367A (zh) 1999-08-11
HUP9802961A2 (hu) 1999-07-28
TR199802648A2 (xx) 1999-07-21
AU9720598A (en) 1999-07-08
PL330451A1 (en) 1999-06-21
CA2255143A1 (en) 1999-06-20
CZ422398A3 (cs) 1999-07-14
TR199802649A2 (xx) 1999-07-21
AR016436A1 (es) 2001-07-04
EP0926237A2 (de) 1999-06-30
KR19990063284A (ko) 1999-07-26
PL330452A1 (en) 1999-06-21

Similar Documents

Publication Publication Date Title
CZ422598A3 (cs) Protein ihnibující p27, DNA kódující takový protein a jejich použití k průkazu RNA, pro hledání inhibitorů a ke stimulaci buněčné proliferace
Cook et al. Two novel targets of the MAP kinase Kss1 are negative regulators of invasive growth in the yeast Saccharomyces cerevisiae.
Harper et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
Kosugi et al. PCF1 and PCF2 specifically bind to cis elements in the rice proliferating cell nuclear antigen gene.
Mochizuki et al. Identification and cDNA cloning of a novel human mosaic protein, LGN, based on interaction with Gαi2
Sharp et al. The vaccinia virus E3L gene product interacts with both the regulatory and the substrate binding regions of PKR: implications for PKR autoregulation
Ghiara et al. A cyclin B homolog in S. cerevisiae: chronic activation of the Cdc28 protein kinase by cyclin prevents exit from mitosis
Hengartner et al. Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-dependent kinases
Ching et al. Cloning of three novel neuronal Cdk5 activator binding proteins
CA2146965C (en) Cyclin complex rearrangement and uses related thereto
Fotedar et al. A conserved domain of the large subunit of replication factor C binds PCNA and acts like a dominant negative inhibitor of DNA replication in mammalian cells.
Prendergast et al. Mbh 1: a novel gelsolin/severin‐related protein which binds actin in vitro and exhibits nuclear localization in vivo.
Fülöp et al. The Medicago CDKC; 1‐CYCLINT; 1 kinase complex phosphorylates the carboxy‐terminal domain of RNA polymerase II and promotes transcription
Janoueix‐Lerosey et al. Identification of a specific effector of the small GTP‐binding protein Rap2
JP2001510347A (ja) IKK−βタンパク質、核酸及び方法
JP3500156B2 (ja) IκBキナーゼ類
Grueneberg et al. Sequence-specific targeting of nuclear signal transduction pathways by homeodomain proteins
NO323532B1 (no) Fremgangsmate for identifisering av kjemoterapeutiske midler ved bruk av transkripsjonsfaktor DP-1
Kolman et al. Serine-173 of the Epstein-Barr virus ZEBRA protein is required for DNA binding and is a target for casein kinase II phosphorylation.
Qian et al. GRSF-1: a poly (A)+ mRNA binding protein which interacts with a conserved G-rich element
Hirano et al. ROM7/BEM4 encodes a novel protein that interacts with the Rho1p small GTP-binding protein in Saccharomyces cerevisiae
US5846764A (en) Materials and methods relating to proteins that interact with casein kinase I
Rao et al. Δelk-1, a Variant of Elk-1, Fails to Interact with the Serum Response Factor and Binds to DNA with Modulated Specificity
JP2001510684A (ja) アッセイ、治療法及び治療手段
Lee et al. Salpα and Salpβ, growth-arresting homologs of Sam68

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic